BioCentury
ARTICLE | Clinical News

Pivanex analog of butyric acid data

November 18, 1996 8:00 AM UTC

ANSNU announced interim analysis of a Phase Ib trial in which half of the planned dose levels have been given. One of 3 patients with lung cancer has had a 50 percent reduction in tumor volume after treatment with Pivanex, which induces apoptosis. Six other patients with various gastrointestinal cancers have not responded to lower doses of the agent. ...